{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:54:19Z","timestamp":1769741659560,"version":"3.49.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Drug clinical comprehensive evaluation project of Health Commission of Guangxi Zhuang Autonomous Region","award":["YPPJ014"],"award-info":[{"award-number":["YPPJ014"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-025-04035-4","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T16:43:04Z","timestamp":1755794584000},"page":"504-518","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-effectiveness of socazolimab plus chemotherapy vs. standard chemotherapy for first-line treatment of extensive-stage small cell lung cancer: a U.S. and China perspective"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-3583-9518","authenticated-orcid":false,"given":"Wenwang","family":"Lang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiangbo","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haiqing","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulong","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinling","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"28","key":"4035_CR1","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/jco.2005.04.4859","volume":"24","author":"R Govindan","year":"2006","unstructured":"Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539\u201344. https:\/\/doi.org\/10.1200\/jco.2005.04.4859.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4035_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"issue":"5 Suppl","key":"4035_CR3","doi-asserted-by":"publisher","first-page":"e400S","DOI":"10.1378\/chest.12-2363","volume":"143","author":"JR Jett","year":"2013","unstructured":"Jett JR, Schild SE, Kesler KA, Kalemkerian GP. Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5 Suppl):e400S \u2013 e419. https:\/\/doi.org\/10.1378\/chest.12-2363.","journal-title":"Chest"},{"issue":"1","key":"4035_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1200\/jop.2015.008201","volume":"12","author":"CM Rudin","year":"2016","unstructured":"Rudin CM, Giaccone G, Ismaila N. Treatment of small-cell lung cancer: American Society of Clinical Oncology endorsement of the American College of Chest Physicians guideline. J Oncol Pract. 2016;12(1):83\u20136. https:\/\/doi.org\/10.1200\/jop.2015.008201.","journal-title":"J Oncol Pract"},{"issue":"14","key":"4035_CR5","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.1200\/jco.2011.40.4905","volume":"30","author":"A Rossi","year":"2012","unstructured":"Rossi A, Di Maio M, Chiodini P, Rudd RM, Okamoto H, Skarlos DV, et al. Carboplatin- or cisplatin-based chemotherapy in first-line treatment of small-cell lung cancer: the COCIS meta-analysis of individual patient data. J Clin Oncol. 2012;30(14):1692\u20138. https:\/\/doi.org\/10.1200\/jco.2011.40.4905.","journal-title":"J Clin Oncol"},{"issue":"10212","key":"4035_CR6","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1016\/s0140-6736(19)32222-6","volume":"394","author":"L Paz-Ares","year":"2019","unstructured":"Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394(10212):1929\u201339. https:\/\/doi.org\/10.1016\/s0140-6736(19)32222-6.","journal-title":"Lancet"},{"issue":"6","key":"4035_CR7","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/s1470-2045(22)00224-8","volume":"23","author":"J Wang","year":"2022","unstructured":"Wang J, Zhou C, Yao W, Wang Q, Min X, Chen G, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(6):739\u201347. https:\/\/doi.org\/10.1016\/s1470-2045(22)00224-8.","journal-title":"Lancet Oncol"},{"issue":"23","key":"4035_CR8","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","volume":"379","author":"L Horn","year":"2018","unstructured":"Horn L, Mansfield AS, Szcz\u0119sna A, Havel L, Krzakowski M, Hochmair MJ, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1809064.","journal-title":"N Engl J Med"},{"issue":"2","key":"4035_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2022.100408","volume":"7","author":"L Paz-Ares","year":"2022","unstructured":"Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7(2): 100408. https:\/\/doi.org\/10.1016\/j.esmoop.2022.100408.","journal-title":"ESMO Open"},{"issue":"6","key":"4035_CR10","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1200\/jco.20.01055","volume":"39","author":"SV Liu","year":"2021","unstructured":"Liu SV, Reck M, Mansfield AS, Mok T, Scherpereel A, Reinmuth N, et al. Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with atezolizumab, carboplatin, and etoposide (IMpower133). J Clin Oncol. 2021;39(6):619\u201330. https:\/\/doi.org\/10.1200\/jco.20.01055.","journal-title":"J Clin Oncol"},{"issue":"12","key":"4035_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1001\/jama.2022.16464","volume":"328","author":"Y Cheng","year":"2022","unstructured":"Cheng Y, Han L, Wu L, Chen J, Sun H, Wen G, et al. Effect of first-line Serplulimab vs placebo added to chemotherapy on survival in patients with extensive-stage small cell lung cancer: the ASTRUM-005 randomized clinical trial. JAMA. 2022;328(12):1223\u201332. https:\/\/doi.org\/10.1001\/jama.2022.16464.","journal-title":"JAMA"},{"issue":"7","key":"4035_CR12","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jtho.2024.03.008","volume":"19","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, et al. Tislelizumab plus platinum and etoposide versus placebo plus platinum and etoposide as first-line treatment for extensive-stage SCLC (rationale-312): a multicenter, double-blind, placebo-controlled, randomized, phase 3 clinical trial. J Thorac Oncol. 2024;19(7):1073\u201385. https:\/\/doi.org\/10.1016\/j.jtho.2024.03.008.","journal-title":"J Thorac Oncol"},{"issue":"10","key":"4035_CR13","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1038\/s41591-024-03132-1","volume":"30","author":"Y Cheng","year":"2024","unstructured":"Cheng Y, Chen J, Zhang W, Xie C, Hu Q, Zhou N, et al. Benmelstobart, anlotinib and chemotherapy in extensive-stage small-cell lung cancer: a randomized phase 3 trial. Nat Med. 2024;30(10):2967\u201376. https:\/\/doi.org\/10.1038\/s41591-024-03132-1.","journal-title":"Nat Med"},{"issue":"4","key":"4035_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2023.100478","volume":"4","author":"S Lu","year":"2023","unstructured":"Lu S, Chen Z, Cui J, Guo R, Li Z, Li BX, et al. Efficacy and safety of anti-programmed death-ligand 1 monoclonal antibody socazolimab with carboplatin and etoposide for extensive-stage SCLC: results from the phase 1b clinical trial. JTO Clin Res Rep. 2023;4(4): 100478. https:\/\/doi.org\/10.1016\/j.jtocrr.2023.100478.","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"4035_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41392-024-02115-5","volume":"10","author":"Z Chen","year":"2025","unstructured":"Chen Z, Chen J, Huang D, Zhang W, Wu L, Yi T, et al. A multicenter, randomized, double-blind, placebo-controlled phase 3 study of Socazolimab or placebo combined with carboplatin and etoposide in the first-line treatment of extensive-stage small cell lung cancer. Signal Transduct Target Ther. 2025;10(1):28. https:\/\/doi.org\/10.1038\/s41392-024-02115-5.","journal-title":"Signal Transduct Target Ther"},{"key":"4035_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyae260","author":"B Tang","year":"2025","unstructured":"Tang B, Xiao J, Chi Z, Duan R, Cui C, Si L, et al. Phase Ib study of anti-PD-L1 monoclonal antibody socazolimab in combination with nab-paclitaxel as first-line therapy for advanced urothelial carcinoma. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyae260.","journal-title":"Oncologist"},{"issue":"2","key":"4035_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.0037","volume":"4","author":"D Su","year":"2021","unstructured":"Su D, Wu B, Shi L. Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma. JAMA Netw Open. 2021;4(2): e210037. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.0037.","journal-title":"JAMA Netw Open"},{"key":"4035_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.vhri.2020.07.580","volume":"24","author":"X Yue","year":"2021","unstructured":"Yue X, Li Y, Wu J, Guo JJ. Current development and practice of pharmacoeconomic evaluation guidelines for universal health coverage in China. Value Health Reg Issues. 2021;24:1\u20135. https:\/\/doi.org\/10.1016\/j.vhri.2020.07.580.","journal-title":"Value Health Reg Issues"},{"issue":"3","key":"4035_CR19","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1002\/(sici)1099-1050(200004)9:3<235::aid-hec502>3.0.co;2-o","volume":"9","author":"CJ Murray","year":"2000","unstructured":"Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9(3):235\u201351. https:\/\/doi.org\/10.1002\/(sici)1099-1050(200004)9:3%3c235::aid-hec502%3e3.0.co;2-o.","journal-title":"Health Econ"},{"issue":"9","key":"4035_CR20","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1056\/NEJMp1405158","volume":"371","author":"PJ Neumann","year":"2014","unstructured":"Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness\u2013the curious resilience of the $50,000-per-QALY threshold. N Engl J Med. 2014;371(9):796\u20137. https:\/\/doi.org\/10.1056\/NEJMp1405158.","journal-title":"N Engl J Med"},{"issue":"5","key":"4035_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1007\/s40258-022-00743-y","volume":"20","author":"D Husereau","year":"2022","unstructured":"Husereau D, Drummond M, Augustovski F, de Bekker-Grob E, Briggs AH, Carswell C, et al. Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations. Appl Health Econ Health Policy. 2022;20(5):781\u20132. https:\/\/doi.org\/10.1007\/s40258-022-00743-y.","journal-title":"Appl Health Econ Health Policy"},{"key":"4035_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1044678","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, Liu K, Qin Q, Zhu H. Serplulimab plus chemotherapy as first-line treatment for extensive-stage small-cell lung cancer: a cost-effectiveness analysis. Front Immunol. 2022;13: 1044678. https:\/\/doi.org\/10.3389\/fimmu.2022.1044678.","journal-title":"Front Immunol"},{"key":"4035_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1092385","volume":"14","author":"L Liu","year":"2023","unstructured":"Liu L, Wang L, Chen L, Ding Y, Zhang Q, Shu Y. Cost-effectiveness of sintilimab plus chemotherapy versus chemotherapy alone as first-line treatment of locally advanced or metastatic oesophageal squamous cell carcinoma. Front Immunol. 2023;14: 1092385. https:\/\/doi.org\/10.3389\/fimmu.2023.1092385.","journal-title":"Front Immunol"},{"key":"4035_CR24","doi-asserted-by":"publisher","DOI":"10.1177\/17588359221122733","author":"X Cao","year":"2022","unstructured":"Cao X, Cai H, Li N, Zheng B, Zheng Z, Liu M. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone for advanced esophageal cancer: a cost-effectiveness analysis. Ther Adv Med Oncol. 2022. https:\/\/doi.org\/10.1177\/17588359221122733.","journal-title":"Ther Adv Med Oncol"},{"key":"4035_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1172242","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu S, Jiang N, Dou L, Li S. Cost-effectiveness analysis of serplulimab plus chemotherapy in the first-line treatment for PD-L1-positive esophageal squamous cell carcinoma in China. Front Immunol. 2023;14: 1172242. https:\/\/doi.org\/10.3389\/fimmu.2023.1172242.","journal-title":"Front Immunol"},{"issue":"2","key":"4035_CR26","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s11136-020-02615-1","volume":"30","author":"A Vedadi","year":"2021","unstructured":"Vedadi A, Shakik S, Brown MC, Lok BH, Shepherd FA, Leighl NB, et al. The impact of symptoms and comorbidity on health utility scores and health-related quality of life in small cell lung cancer using real world data. Qual Life Res. 2021;30(2):445\u201354. https:\/\/doi.org\/10.1007\/s11136-020-02615-1.","journal-title":"Qual Life Res"},{"issue":"5","key":"4035_CR27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.8065","volume":"4","author":"R Pei","year":"2021","unstructured":"Pei R, Shi Y, Lv S, Dai T, Zhang F, Liu S, et al. Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis. JAMA Netw Open. 2021;4(5): e218065. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.8065.","journal-title":"JAMA Netw Open"},{"key":"4035_CR28","unstructured":"Centers_for_Medicare_and_Medicaid_Services. Medicare physician fee schedule look-up tool. Centers for Medicare and Medicaid Services. 2025. https:\/\/www.cms.gov\/medicare\/physicianfee-schedule\/search. Accessed 28 Jan 2025."},{"issue":"2","key":"4035_CR29","doi-asserted-by":"publisher","first-page":"153","DOI":"10.6004\/jnccn.2020.7621","volume":"19","author":"R Mehra","year":"2021","unstructured":"Mehra R, Yong C, Seal B, van Keep M, Raad A, Zhang Y. Cost-effectiveness of durvalumab after chemoradiotherapy in unresectable stage III NSCLC: a US healthcare perspective. J Natl Compr Canc Netw. 2021;19(2):153\u201362. https:\/\/doi.org\/10.6004\/jnccn.2020.7621.","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"4035_CR30","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s40259-023-00586-6","volume":"37","author":"T Shao","year":"2023","unstructured":"Shao T, Zhao M, Liang L, Tang W. Serplulimab plus chemotherapy vs chemotherapy for treatment of US and Chinese patients with extensive-stage small-cell lung cancer: a cost-effectiveness analysis to inform drug pricing. BioDrugs. 2023;37(3):421\u201332. https:\/\/doi.org\/10.1007\/s40259-023-00586-6.","journal-title":"BioDrugs"},{"key":"4035_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.699781","volume":"11","author":"Q Liu","year":"2021","unstructured":"Liu Q, Luo X, Yi L, Zeng X, Tan C. First-line chemo-immunotherapy for extensive-stage small-cell lung cancer: a United States-based cost-effectiveness analysis. Front Oncol. 2021;11: 699781. https:\/\/doi.org\/10.3389\/fonc.2021.699781.","journal-title":"Front Oncol"},{"issue":"5","key":"4035_CR32","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1007\/s11096-024-01752-8","volume":"46","author":"J Wei","year":"2024","unstructured":"Wei J, Xu K, Lin Y, Liu Q, Zhou C, Zhang P, et al. Economic evaluation of camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma in the United States and China. Int J Clin Pharm. 2024;46(5):1189\u201399. https:\/\/doi.org\/10.1007\/s11096-024-01752-8.","journal-title":"Int J Clin Pharm"},{"issue":"6","key":"4035_CR33","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1007\/s11096-024-01802-1","volume":"46","author":"W Lang","year":"2024","unstructured":"Lang W, Ai Q, He Y, Pan Y, Jiang Q, Ouyang M, et al. Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China. Int J Clin Pharm. 2024;46(6):1536\u201345. https:\/\/doi.org\/10.1007\/s11096-024-01802-1.","journal-title":"Int J Clin Pharm"},{"key":"4035_CR34","unstructured":"NCCN. Clinical practice guidelines in oncology: Small cell lung cancer. National Comprehensive Cancer Net-work. 2025. www.nccn.org\/patients. Accessed 28 Jan 2025."},{"key":"4035_CR35","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.650392","volume":"9","author":"Y Wang","year":"2021","unstructured":"Wang Y, Rui M, Yang L, Wang X, Shang Y, Ma A, et al. Economic evaluation of first-line Atezolizumab for extensive-stage small-cell lung cancer in the US. Front Public Health. 2021;9: 650392. https:\/\/doi.org\/10.3389\/fpubh.2021.650392.","journal-title":"Front Public Health"},{"issue":"10","key":"4035_CR36","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.6004\/jnccn.2020.7796","volume":"19","author":"D Ding","year":"2021","unstructured":"Ding D, Hu H, Li S, Zhu Y, Shi Y, Liao M, et al. Cost-effectiveness analysis of Durvalumab plus chemotherapy in the first-line treatment of extensive-stage small cell lung cancer. J Natl Compr Canc Netw. 2021;19(10):1141\u20137. https:\/\/doi.org\/10.6004\/jnccn.2020.7796.","journal-title":"J Natl Compr Canc Netw"},{"key":"4035_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.lungcan.2019.01.019","volume":"130","author":"K Zhou","year":"2019","unstructured":"Zhou K, Zhou J, Huang J, Zhang N, Bai L, Yang Y, et al. Cost-effectiveness analysis of atezolizumab plus chemotherapy in the first-line treatment of extensive-stage small-cell lung cancer. Lung Cancer. 2019;130:1\u20134. https:\/\/doi.org\/10.1016\/j.lungcan.2019.01.019.","journal-title":"Lung Cancer"},{"key":"4035_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1484650","volume":"14","author":"C You","year":"2024","unstructured":"You C, Zhang J, Lei J, Fu W, Zheng B, Liu M, et al. Cost-effectiveness analysis of anlotinib plus chemotherapy with or without benmelstobart versus chemotherapy alone for extensive-stage small-cell lung cancer in China. Front Oncol. 2024;14: 1484650. https:\/\/doi.org\/10.3389\/fonc.2024.1484650.","journal-title":"Front Oncol"},{"issue":"5","key":"4035_CR39","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1080\/14737167.2025.2483423","volume":"25","author":"S Zhao","year":"2025","unstructured":"Zhao S, Kang S. Comprehensive economic value evaluation of adding tislelizumab to first-line chemotherapy for patients with extensive-stage small cell lung cancer in China. Expert Rev Pharmacoecon Outcomes Res. 2025;25(5):805\u201311. https:\/\/doi.org\/10.1080\/14737167.2025.2483423.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"4035_CR40","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1556100","volume":"16","author":"J Yang","year":"2025","unstructured":"Yang J, Chen F, Li J, Zhou Y, Wang H, Long Y. Cost-effectiveness analysis of Toripalimab regimen for extensive-stage small-cell lung cancer in China and America. Front Immunol. 2025;16: 1556100. https:\/\/doi.org\/10.3389\/fimmu.2025.1556100.","journal-title":"Front Immunol"},{"key":"4035_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1591517","volume":"16","author":"L Zhang","year":"2025","unstructured":"Zhang L, Chen H, Zhu H, Zheng Z. Toripalimab plus chemotherapy versus chemotherapy as first-line therapy for extensive-stage small cell lung cancer: a cost-effectiveness analysis. Front Immunol. 2025;16: 1591517. https:\/\/doi.org\/10.3389\/fimmu.2025.1591517.","journal-title":"Front Immunol"},{"issue":"8","key":"4035_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-072106","volume":"13","author":"Y Long","year":"2023","unstructured":"Long Y, Xu Y, Liao L, Zhou Y, Wang H. Cost-effectiveness analysis of serplulimab combined with chemotherapy in the treatment of extensive-stage small-cell lung cancer from the perspective of the healthcare system in China. BMJ Open. 2023;13(8): e072106. https:\/\/doi.org\/10.1136\/bmjopen-2023-072106.","journal-title":"BMJ Open"},{"key":"4035_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223020","volume":"14","author":"G Xiang","year":"2023","unstructured":"Xiang G, Jiang T, Gan L, Wu Y, Zhang N, Xing H, et al. Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China. Front Immunol. 2023;14: 1223020. https:\/\/doi.org\/10.3389\/fimmu.2023.1223020.","journal-title":"Front Immunol"},{"issue":"8","key":"4035_CR44","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1080\/14737167.2024.2379600","volume":"24","author":"H Xiang","year":"2024","unstructured":"Xiang H, Meng K, Wu M, Tan C. Cost-effectiveness analysis of first-line serplulimab plus chemotherapy for advanced squamous non-small-cell lung cancer in China: based on the ASTRUM-004 trial. Expert Rev Pharmacoecon Outcomes Res. 2024;24(8):1043\u201351. https:\/\/doi.org\/10.1080\/14737167.2024.2379600.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-025-04035-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-025-04035-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T13:47:21Z","timestamp":1769694441000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12094-025-04035-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["4035"],"URL":"https:\/\/doi.org\/10.1007\/s12094-025-04035-4","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"2 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or nonfinancial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study did not involve human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}